| Recruiting | JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies B-cell Malignancies | N/A | 2025-07-01 |
| Recruiting | Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Soli CDH17-positive Advanced Solid Tumors | EARLY_Phase 1 | 2025-03-01 |
| Recruiting | JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | 2024-10-09 |
| Recruiting | Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Relapsed/Refractory Multiple Myeloma | N/A | 2024-07-01 |
| Recruiting | JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) B-cell Acute Lymphoblastic Leukemia (B-ALL) | EARLY_Phase 1 | 2024-06-20 |
| Recruiting | Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | 2024-02-01 |
| Terminated | C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma Lymphoma, B-Cell, CAR-T | Phase 1 | 2023-12-24 |
| Terminated | Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML Acute Myeloid Leukemia | EARLY_Phase 1 | 2023-10-10 |
| Unknown | A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors | Phase 1 / Phase 2 | 2023-07-01 |
| Unknown | A Study of RD14-01 in Patients With Advanced Solid Tumors Solid Tumor | Phase 1 / Phase 2 | 2023-02-08 |
| Unknown | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 / Phase 2 | 2023-02-07 |
| Unknown | A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies B-Cell Lymphoblastic Leukemia/Lymphoma | Phase 1 / Phase 2 | 2022-12-08 |
| Unknown | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL B-cell Acute Lymphoblastic Leukemia, B-ALL | Phase 1 / Phase 2 | 2022-12-05 |
| Withdrawn | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma | EARLY_Phase 1 | 2021-12-01 |
| Unknown | CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malig Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B-cell Non-hodgkin Lymphoma | EARLY_Phase 1 | 2021-09-29 |
| Unknown | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia Acute Myeloid Leukemia | EARLY_Phase 1 | 2021-09-14 |
| Withdrawn | UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies B-cell Lymphoma | EARLY_Phase 1 | 2021-08-20 |
| Withdrawn | CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL B-cell Lymphoma | Phase 1 | 2021-05-05 |